MD4590B1 - Derivaţi macrociclici pentru tratamentul bolilor proliferative - Google Patents

Derivaţi macrociclici pentru tratamentul bolilor proliferative

Info

Publication number
MD4590B1
MD4590B1 MDA20140086A MD20140086A MD4590B1 MD 4590 B1 MD4590 B1 MD 4590B1 MD A20140086 A MDA20140086 A MD A20140086A MD 20140086 A MD20140086 A MD 20140086A MD 4590 B1 MD4590 B1 MD 4590B1
Authority
MD
Moldova
Prior art keywords
treatment
compounds
proliferative diseases
salts
macrocyclic derivatives
Prior art date
Application number
MDA20140086A
Other languages
English (en)
Russian (ru)
Other versions
MD4590C1 (ro
MD20140086A2 (ro
Inventor
Саймон Бейли
Бенджамин Джозеф БЁРК
Майкл Раймонд КОЛЛИНС
Цзинжун Джин Цуй
Джудит Гейл Дил
Роберт Луис Хоффман
Циньхуа Хуан
Тед Уильям ДЖОНСОН
Роберт Стивен Кания
Джон Чарльз Кат
Фыонг Тхи Куи Ле
Мишель Энн Мактиг
Синтия Луиза Палмер
Пол Фрэнсис Ричардсон
Нил Уильям СЕЙЧ
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4590(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of MD20140086A2 publication Critical patent/MD20140086A2/ro
Publication of MD4590B1 publication Critical patent/MD4590B1/ro
Publication of MD4590C1 publication Critical patent/MD4590C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Invenţia se referă la compuşi cu formula (I)(I)unde substituenţii sunt definiţi în descriere şi la sărurile farmaceutice acceptabile ale acestora, la compoziţii farmaceutice ce conţin compuşii (I) şi sărurile lor şi la utilizarea acestora. Compuşii şi sărurile (I) inhibă kinaza limfomului anaplastic (ALK) şi/sau EML4-ALK şi sunt utili pentru tratamentul sau ameliorarea tulburarilor proliferative celulare anormale, cum ar fi cancerul.
MDA20140086A 2012-03-06 2013-02-20 Derivaţi macrociclici pentru tratamentul bolilor proliferative MD4590C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607485P 2012-03-06 2012-03-06
US201361759307P 2013-01-31 2013-01-31
PCT/IB2013/051391 WO2013132376A1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
MD20140086A2 MD20140086A2 (ro) 2015-01-31
MD4590B1 true MD4590B1 (ro) 2018-08-31
MD4590C1 MD4590C1 (ro) 2019-03-31

Family

ID=48142828

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140086A MD4590C1 (ro) 2012-03-06 2013-02-20 Derivaţi macrociclici pentru tratamentul bolilor proliferative

Country Status (46)

Country Link
US (2) US8680111B2 (ro)
EP (1) EP2822953B9 (ro)
JP (2) JP5823066B2 (ro)
KR (1) KR101692600B1 (ro)
CN (1) CN104169286B (ro)
AP (1) AP2014007881A0 (ro)
AR (1) AR090230A1 (ro)
AU (1) AU2013229173B2 (ro)
BR (1) BR112014022106B1 (ro)
CA (1) CA2863892C (ro)
CL (1) CL2014002084A1 (ro)
CO (1) CO7061081A2 (ro)
CR (1) CR20140370A (ro)
CY (2) CY1118771T1 (ro)
DK (1) DK2822953T5 (ro)
DO (1) DOP2014000188A (ro)
EA (1) EA026155B9 (ro)
ES (1) ES2621220T3 (ro)
FR (1) FR19C1062I2 (ro)
GE (1) GEP201606560B (ro)
GT (1) GT201400187A (ro)
HK (1) HK1199247A1 (ro)
HR (1) HRP20170287T2 (ro)
HU (2) HUE034118T2 (ro)
IL (1) IL234062A (ro)
LT (2) LT2822953T (ro)
LU (1) LUC00131I2 (ro)
MD (1) MD4590C1 (ro)
ME (1) ME02630B (ro)
MX (1) MX350844B (ro)
MY (1) MY169142A (ro)
NI (1) NI201400102A (ro)
NL (1) NL301006I2 (ro)
NO (1) NO2019034I1 (ro)
NZ (1) NZ627900A (ro)
PE (1) PE20142339A1 (ro)
PH (1) PH12014501992B1 (ro)
PL (1) PL2822953T3 (ro)
PT (1) PT2822953T (ro)
RS (1) RS55814B1 (ro)
SG (1) SG11201404451TA (ro)
SI (1) SI2822953T1 (ro)
TW (1) TWI476199B (ro)
UY (1) UY34657A (ro)
WO (1) WO2013132376A1 (ro)
ZA (1) ZA201406244B (ro)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35288A (es) 2013-01-31 2014-08-29 Vertex Pharma Piridonamidas como moduladores de canales de sodio
CA2916605C (en) 2013-06-28 2018-04-24 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
AP2016009287A0 (en) 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
MY193524A (en) 2014-01-24 2022-10-18 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
CN103772272A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-溴吡啶的合成方法
EP3183256A4 (en) * 2014-08-20 2018-05-30 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
KR102569226B1 (ko) * 2014-10-13 2023-08-22 아트린 파마슈티컬스 엘엘씨 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
BR112017013982A2 (pt) * 2015-01-16 2018-01-02 Chugai Seiyaku Kabushiki Kaisha fármaco de combinação
KR102599788B1 (ko) 2015-07-02 2023-11-07 터닝 포인트 테라퓨틱스, 인크. 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클
LT3319969T (lt) 2015-07-06 2024-06-10 Turning Point Therapeutics, Inc. Diarilo makrociklo polimorfas
JP6817287B2 (ja) 2015-07-21 2021-01-20 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キラルジアリール大環状分子及びその使用
RU2018101363A (ru) 2015-07-31 2019-08-29 Пфайзер Инк. Кристаллическая форма свободного основания лорлатиниба
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN112920201A (zh) * 2016-03-03 2021-06-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN105732355A (zh) * 2016-04-07 2016-07-06 戊言医药科技（上海）有限公司 1-(5-氟-2-碘苯基)乙酮的制备方法
CN105646355A (zh) * 2016-04-07 2016-06-08 戊言医药科技（上海）有限公司 3-(羟甲基)-1-甲基-吡唑-5-甲腈的制备方法
EP3440086B1 (en) 2016-04-08 2020-08-12 Pfizer Inc. Crystalline forms of lorlatinib maleate
US10301324B2 (en) 2016-04-12 2019-05-28 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
CN105801603B (zh) * 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
WO2018137679A1 (en) * 2017-01-25 2018-08-02 Teligene Ltd Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
ES2927712T3 (es) 2017-05-16 2022-11-10 Vertex Pharma Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
PE20200608A1 (es) 2017-06-30 2020-03-10 Bayer Animal Health Gmbh Nuevos derivados de azaquinolina
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
SG11202002445SA (en) 2017-10-10 2020-04-29 Pfizer Crystalline form of lorlatinib free base hydrate
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
EP4151641A1 (en) 2017-12-19 2023-03-22 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating cancer
CA3091012A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
US20210163498A1 (en) 2018-04-23 2021-06-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
CN111918868B (zh) * 2018-05-04 2022-12-30 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN108621206B (zh) * 2018-05-07 2020-08-14 昆山国显光电有限公司 手套箱系统以及手套箱系统的保养方法
EP3854397A4 (en) * 2018-09-18 2022-07-13 Kabushiki Kaisha Yakult Honsha CANCER MULTIPLE THERAPY USING A QUINOLINE CARBOXAMIDE DERIVATIVE
CN109081810A (zh) * 2018-09-20 2018-12-25 沈阳药科大学 1-甲基-3–((甲氨基)甲基)-1h-吡唑-5-腈的合成方法
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
US20220024908A1 (en) * 2018-11-28 2022-01-27 Shenzhen Targetrx, Inc. Preparation method for deuterated macrocyclic compound
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109651397A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼中间体及制备劳拉替尼的方法
CN109651418A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼原料药合成中间体及有机金属钯催化偶联制备劳拉替尼的方法
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
CN111499514A (zh) * 2019-01-31 2020-08-07 连云港润众制药有限公司 一种罗沙司他中间体的制备方法
EP3941457A4 (en) 2019-03-21 2023-04-26 Merck Sharp & Dohme LLC HISTONE-DEACETYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
EP3844166B1 (en) * 2019-05-14 2023-07-12 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
EP3999514A1 (en) * 2019-07-18 2022-05-25 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112812128B (zh) * 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CN111170908B (zh) * 2020-01-09 2021-08-17 北京印刷学院 一种2，4-二甲基-3-甲磺酰基卤苯的合成方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
CA3179702A1 (en) * 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2021226208A2 (en) * 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
EP4137495A4 (en) * 2020-05-18 2023-09-20 Shenzhen TargetRx, Inc. SOLID FORM OF MACROCYCLIC COMPOUND, ITS PREPARATION AND USE
WO2022011123A1 (en) * 2020-07-10 2022-01-13 Blossomhill Therapeutics, Inc. Macrocycles and their use
EP4262796A1 (en) * 2020-12-17 2023-10-25 Blossomhill Therapeutics, Inc. Macrocycles and their use
CN114805371B (zh) * 2021-01-19 2024-05-24 江苏开元药业有限公司 含2-氨基嘧啶大环类化合物及其制备方法和用途
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115246843A (zh) * 2021-04-26 2022-10-28 苏州东南药业股份有限公司 一类十四元稠环衍生物及其应用
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
TW202320768A (zh) * 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
WO2023156983A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa Compounds and compositions for neurodegenerative diseases
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN115746023A (zh) * 2022-10-27 2023-03-07 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
AP2114A (en) 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
MX2007002248A (es) 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
EP1784396B8 (en) 2004-08-26 2011-04-20 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
GEP20104906B (en) * 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
EP1963302B1 (en) 2005-12-05 2013-02-27 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor
BRPI0619424B1 (pt) 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
EP2120578B1 (en) 2007-01-19 2014-11-19 Xcovery, INC. Kinase inhibitor compounds
ATE553107T1 (de) 2007-03-01 2012-04-15 Chugai Pharmaceutical Co Ltd Makrocyclische verbindung
CU20090155A7 (es) * 2007-03-13 2011-04-26 Pfizer Prod Inc Macrolidos
EP2265270A1 (en) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
JP2011518836A (ja) * 2008-04-24 2011-06-30 インサイト・コーポレイション 大環状化合物およびそれらのキナーゼ阻害剤としての使用
JP5531011B2 (ja) * 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体
KR20110073500A (ko) * 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2011047926A1 (en) 2009-10-21 2011-04-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
US8383793B2 (en) * 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011138751A2 (en) * 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
KR102132405B1 (ko) * 2010-05-20 2020-07-09 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
WO2012016186A1 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
EP2686323A1 (en) 2011-03-16 2014-01-22 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors

Also Published As

Publication number Publication date
US8680111B2 (en) 2014-03-25
GEP201606560B (en) 2016-10-25
HUE034118T2 (en) 2018-01-29
HUS1900040I1 (hu) 2019-09-30
BR112014022106B1 (pt) 2022-08-02
LTC2822953I2 (lt) 2020-12-28
KR20140137414A (ko) 2014-12-02
JP6002825B2 (ja) 2016-10-05
CN104169286A (zh) 2014-11-26
CY2019033I1 (el) 2019-11-27
CL2014002084A1 (es) 2014-11-03
WO2013132376A1 (en) 2013-09-12
GT201400187A (es) 2015-10-15
CO7061081A2 (es) 2014-09-19
ZA201406244B (en) 2015-05-27
PL2822953T3 (pl) 2017-07-31
JP2016041709A (ja) 2016-03-31
CR20140370A (es) 2014-08-21
EP2822953B1 (en) 2017-02-01
EP2822953B9 (en) 2017-06-21
HRP20170287T2 (hr) 2017-11-03
DOP2014000188A (es) 2014-11-16
PE20142339A1 (es) 2015-01-15
HRP20170287T1 (hr) 2017-04-21
TWI476199B (zh) 2015-03-11
BR112014022106A2 (pt) 2017-07-11
DK2822953T3 (en) 2017-04-03
CA2863892A1 (en) 2013-09-12
AP2014007881A0 (en) 2014-08-31
CN104169286B (zh) 2016-06-08
US20130252961A1 (en) 2013-09-26
PH12014501992A1 (en) 2014-11-24
KR101692600B1 (ko) 2017-01-03
FR19C1062I2 (fr) 2020-09-04
ES2621220T9 (es) 2017-11-23
TW201350484A (zh) 2013-12-16
IL234062A (en) 2017-08-31
MY169142A (en) 2019-02-18
FR19C1062I1 (ro) 2019-11-22
LUC00131I2 (ro) 2020-07-16
MD4590C1 (ro) 2019-03-31
EA026155B1 (ru) 2017-03-31
EA201491394A1 (ru) 2015-05-29
JP2015510879A (ja) 2015-04-13
AU2013229173A1 (en) 2014-08-21
US20140135339A1 (en) 2014-05-15
HK1199247A1 (zh) 2015-06-26
NI201400102A (es) 2015-03-05
CY2019033I2 (el) 2019-11-27
ES2621220T3 (es) 2017-07-03
NL301006I2 (nl) 2020-04-14
CA2863892C (en) 2016-08-30
LUC00131I1 (ro) 2019-10-11
MD20140086A2 (ro) 2015-01-31
SG11201404451TA (en) 2014-09-26
SI2822953T1 (sl) 2017-04-26
PT2822953T (pt) 2017-04-06
PH12014501992B1 (en) 2014-11-24
JP5823066B2 (ja) 2015-11-25
RS55814B1 (sr) 2017-08-31
EA026155B9 (ru) 2017-06-30
EP2822953A1 (en) 2015-01-14
MX350844B (es) 2017-09-22
AU2013229173B2 (en) 2017-06-01
AR090230A1 (es) 2014-10-29
NO2019034I1 (no) 2019-08-19
CY1118771T1 (el) 2017-07-12
NZ627900A (en) 2016-08-26
UY34657A (es) 2013-10-31
ME02630B (me) 2017-06-20
LTPA2019519I1 (lt) 2019-11-11
US9133215B2 (en) 2015-09-15
LT2822953T (lt) 2017-04-10
MX2014010716A (es) 2014-09-22
DK2822953T5 (en) 2017-09-11

Similar Documents

Publication Publication Date Title
MD4590B1 (ro) Derivaţi macrociclici pentru tratamentul bolilor proliferative
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
MY177344A (en) Compounds and their methods of use
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MY191358A (en) Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX340300B (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
MX2012008328A (es) Derivados de pirazina.
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
UA110293C2 (en) Macrocyclic derivatives for the treatment of proliferative diseases
CU20140107A7 (es) Derivados macrocíclicos para el tratamiento de enfermedades
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders

Legal Events

Date Code Title Description
FG4A Patent for invention issued